Overview

Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
AgelessRx
Treatments:
Naltrexone
Niacinamide